Physician profile
Kristin E Doyle
NPI 1801102041
$1,917.13
in general payments reported to CMS, 2019-2025
14 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $243 · 2021: $122 · 2022: $258 · 2023: $609 · 2024: $127 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,159 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,158.53 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $326.21 | 2023-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $244.02 | 2021-2023 | Cequa |
| Sight Sciences, INC. | $243.31 | 2022-2025 | Omni Surgical System |
| Abbvie INC. | $198.25 | 2023-2025 | Durysta |
| Coopervision INC. | $192.92 | 2022-2023 | Clariti Contact Lens |
| Maculogix, INC. | $131.20 | 2020 | |
| Harrow Eye, LLC | $125.00 | 2025 | Vevye |
| Johnson & Johnson Surgical Vision, INC. | $109.28 | 2024 | Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $102.79 | 2019 | |
| Horizon Therapeutics Plc | $99.42 | 2023 | Tepezza |
| Lombart Brothers, INC. | $92.71 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Bausch & Lomb Americas INC. | $17.84 | 2024 | Miebo |
| Alcon Vision LLC | $14.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.